(2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-[2-hydroxy-3-(1,1-dimethyl-2-morpholinocarbonylaminoethyl)aminopropoxy]phenyl]-propionate | 133242-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-[2-hydroxy-3-(1,1-dimethyl-2-morpholinocarbonylaminoethyl)aminopropoxy]phenyl]-propionate
• 英文别名: (2,2-Dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-[2-hydroxy-3-[[2-methyl-1-(morpholine-4-carbonylamino)propan-2-yl]amino]propoxy]phenyl]propanoate
• CAS: 133242-34-9
• 化学式: C₂₇H₄₃N₃O₈
• 分子量: 537.654
• InChiKey: IUTQVVFKOXWUJP-UHFFFAOYSA-N

物化性质

• 沸点：
  731.3±60.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  38
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  128
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2,2-二甲基-1,3-二氧环戊基-4-甲醇对甲基苯磺酸酯 在 氢氧化钾 、 potassium carbonate 作用下， 以 二甲基亚砜 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 31.0h， 生成 (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-[4-[2-hydroxy-3-(1,1-dimethyl-2-morpholinocarbonylaminoethyl)aminopropoxy]phenyl]-propionate
  参考文献：
  名称：

  Development of a Highly Cardioselective Ultra Short-Acting .BETA.-Blocker, ONO-1101.

  摘要：

  一种新型、高度心脏选择性超短效β受体阻滞剂ONO-1101已研发成功，可用于心动过速的紧急治疗和手术中更好地控制心率。该药物在体内的β受体阻断活性比艾司洛尔强约9倍，在体外的心脏选择性比艾司洛尔强8倍。这种β受体阻断药物的作用时间短，如果出现副作用，停药后即可迅速恢复。它可安全用于急性心脏病患者，是心脏病治疗领域的一大进步。

  DOI：

  10.1248/cpb.40.1462

文献信息

• Novel esters of phenylalkanoic acid
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP0397031A1

  公开（公告）日：1990-11-14

  The esters of phenylalkanoic acid of the formula: wherein R¹ is 4-10 membered, saturated or unsaturated, mono- or bi-cyclic hetero ring containing as hetero atoms: (i) one or two nitrogen, (ii) two or three of nitrogen and sulfur in total, or (iii) one or two sulfur; R² is hydrogen; or R¹ and R², taken together with a nitrogen to which they are attached, form 4-7 membered, saturated or unsaturated, mono-­cyclic hetero ring containing as hetero atoms: (i) one or two nitrogen, or (ii) two or three of nitrogen and oxygen in total, the aforementioned hetero rings, represented by R¹ or formed by R¹ and R², taken together with a nitrogen to which they are attached, may be substituted by one substituent selected from C1-4 alkyl and C2-5 acyl; R³ each, independently, is hydrogen or C1-4 alkyl; R⁴ is hydrogen, halogen, trihalomethyl, C1-4 alkyl, C1-4 alkoxyl C2-5 acyl, cyano, nitro or nitroxy; R⁵ each, independently, is hydrogen, C1-4 alkyl or phenyl; or the two R⁵'s, taken together with a carbon to which they are attached, form cyclopentane or cyclohexane; and the pharmaceutically acceptable acid addition salts thereof, have β₁-adrenergic receptor blocking activity, and therefore, are useful for the prevention of and/or in the treatment of cardiovascular diseases such as angina pectoris, myocardial infarction, congestive heart failure, hypertension, arrhythmia, etc.

  该公式化合物为苯基烷酸酯，其化学式为：其中R¹为4-10个成员的饱和或不饱和的单环或双环杂环，其杂原子包括：（i）一个或两个氮原子，（ii）两个或三个氮和硫原子的总和，或（iii）一个或两个硫原子；R²为氢；或R¹和R²与它们连接的氮一起形成4-7个成员的饱和或不饱和的单环杂环，其杂原子包括：（i）一个或两个氮原子，或（ii）两个或三个氮和氧原子的总和，前述由R¹代表或由R¹和R²形成的杂环，与它们连接的氮一起，可以被C1-4烷基和C2-5酰基中的一种取代；R³各自独立地为氢或C1-4烷基；R⁴为氢、卤素、三卤甲基、C1-4烷基、C1-4烷氧基、C2-5酰基、氰基、硝基或亚硝基；R⁵各自独立地为氢、C1-4烷基或苯基；或两个R⁵与它们连接的碳一起形成环戊烷或环己烷；以及它们的药学上可接受的酸盐，具有β₁肾上腺素能受体阻滞活性，因此，可用于预防和/或治疗心血管疾病，如心绞痛、心肌梗死、充血性心力衰竭、高血压、心律失常等。
• US5013734A
  申请人：——

  公开号：US5013734A

  公开（公告）日：1991-05-07
• Development of a Highly Cardioselective Ultra Short-Acting .BETA.-Blocker, ONO-1101.
  作者：Sadahiko IGUCHI、Hiroyuki IWAMURA、Minoru NISHIZAKI、Akio HAYASHI、Kazuhiko SENOKUCHI、Kaoru KOBAYASHI、Katsuhito SAKAKI、Katsutoshi HACHIYA、Yumiko ICHIOKA、Masanori KAWAMURA

  DOI：10.1248/cpb.40.1462

  日期：——

  A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.

  一种新型、高度心脏选择性超短效β受体阻滞剂ONO-1101已研发成功，可用于心动过速的紧急治疗和手术中更好地控制心率。该药物在体内的β受体阻断活性比艾司洛尔强约9倍，在体外的心脏选择性比艾司洛尔强8倍。这种β受体阻断药物的作用时间短，如果出现副作用，停药后即可迅速恢复。它可安全用于急性心脏病患者，是心脏病治疗领域的一大进步。